To determine viral and immune factors involved in transmission and control of HIV-1 infection in persons without functional CCR5.
Introduction
HIV-1 that uses CCR5 for entry (R5 virus) plays an important role in early infection. A 32 base-pair deletion in CCR5 (D32) alters its structure and expression making it unusable by R5 virus. The prevalence of CCR5 D32 homozygosity (CCR5 D32/D32 ) is approximately 1% in the Northern European population and rare in other ethnic groups [1] . CCR5 D32 homozygosity confers a high degree of resistance against infection by HIV-1, and, as a result, only a handful of CCR5 D32/D32 HIV-infected individuals have been identified. All CCR5 D32/D32 patients reported to date have been infected with viruses that are able to use CXCR4 for entry (X4 virus or dual/ mixed tropic virus). A majority of these individuals experience rapid loss of CD4 þ T cells [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , a phenomenon that also has been described in cohorts of CCR5 wild-type patients infected with X4 virus [7, [17] [18] [19] [20] [21] [22] [23] [24] .
Understanding transmission and control of HIV-1 in persons homozygous for CCR5 D32 is important given efforts to develop HIV-1 curative therapies aimed at modifying or disrupting CCR5 expression [25] [26] [27] . Emergence of X4-dual/mixed tropic virus in many patients over time may be due to changes in the availability of CCR5-expressing target cells [28] , an observation supported by the report of viral rebound and R5 to X4 coreceptor-usage switching in an individual following allogeneic stem cell transplantation with CCR5 D32/D32 cells [29] . The study of HIV-1-infected CCR5 D32/D32 individuals has the potential to provide valuable insights into mechanisms of HIV-1 transmission, disease progression and the evolution of coreceptor usage in the setting of CCR5 modification.
Although HIV-1 predominately uses CCR5 and/or CXCR4 for cell entry, a proportion of HIV and simian immunodeficiency virus (SIV) strains have the capacity to use alternative coreceptors other than CCR5 or CXCR4 [5, 6, 8, [30] [31] [32] [33] [34] [35] . Use of alterative coreceptors by HIV-1 from an individual heterozygous for CCR5 D32, and exclusive use of GPR15 by HIV-1 during primary infection in one CCR5 wild-type patient have previously been observed [35, 36] . These findings suggest that alternative coreceptors may play a role in HIV-1 transmission and infection in patients with reduced CCR5 expression and function, but the role of HIV-1 alternative coreceptor use in CCR5 D32/D32 individuals is unknown.
We identified two CCR5 D32/D32 individuals with persistent, low-level plasma HIV-1 loads in the absence of antiretroviral therapy (ART) and determined the coreceptor usage of their viruses. We also assessed evolution of HIV-1 env by single-genome analysis of fulllength env sequences from one participant and his sexual partner, and explored HIV-1 immune responses and escape mutations associated with increased viremia (virologic escape) and disease progression.
Methods
Patient samples and CCR5 genotyping CCR5 D32/D32 patients were identified from a genomewide association study of HIV-1 disease control, including nucleotide polymorphisms in viral coreceptor genes [37] . Subsequent PCR screening of peripheral blood mononuclear cell (PBMC) DNA for the presence of two mutant CCR5 copies was then performed as described [38] . Bidirectional sequencing of CCR5 was performed to verify the findings from PCR screening. Plasma, cryopreserved PBMCs, and clinical laboratory information were obtained from the International HIV Controllers Study (http://ragoninstitute.org/hivcontrol lers). Plasma from a sexual partner of one participant thought to be the source of HIV-1 transmission was also obtained. The Partners Healthcare institutional review board approved this study.
Phenotypic viral coreceptor usage
Virus was concentrated by centrifuging 500-1000 ml of plasma at 17 000 Â g for 1.5 h at 48C prior to RNA extraction using the QIAamp Viral RNA Mini Kit (Qiagen, Valencia, California, USA). Envelope genes were then amplified using nested PCR as described [39, 40] . Full-length env sequences were amplified and sequenced from PBMC DNA extracted using the QIAamp DNA Mini Kit (Qiagen). PCRs were performed in triplicate wells and combined prior to further processing. Bidirectional sequencing of fulllength envelope was performed using published primers [41] . Population or single-genome sequences of the third variable loop (V3) of HIV-1 envelope were applied to the geno2pheno coreceptor usage prediction algorithm [42] .
An in-house phenotypic assay able to detect minority X4 or dual/mixed tropic virus present at 1% or greater of the virus population using pseudoviruses incorporating a luciferase reporter gene and full-length env amplicons from population or single-genome viral RNA was performed as described [40] . Phenotyping was repeated if the luciferase signal on indicator cell lines was less than 20-fold higher than the signal generated from envelopedeleted pseudoviral vectors alone.
Plasma virus recovery and expansion
If RNA extraction and subsequent PCR amplification failed to yield envelope sequences, nested primers for HIV-1 subtypes A through F were used to attempt HIV-1 env, gag, and nef gene amplification as described [41] . A viral expansion protocol was implemented in which 500 ml of plasma was added to 2 million uninfected CD4 þ T-cell blasts stimulated with aCD3/CD28 antibodies (100 ng/ ml) and interleukin-2 (100 units/ml); MOLT4-CCR5 feeder cells were added on day 2. Viral RNA was extracted from culture supernatants concentrated by centrifugation on day 7 and subjected to reverse transcription and realtime PCR quantification as above.
Phenotypic determination of alternative viral coreceptor usage
We performed infectivity assays using GHOST [3] cell lines obtained from the NIH AIDS Research and Reference Reagent Program [30] . Parental cell lines that express CD4 þ but no other viral coreceptors in addition to lines expressing CCR1, CCR2b, CCR3, CCR4, CXCR4, CCR5, CCR8, BOB/GPR15, CXCR6 (BONZO/STRL33), and V28/CX3CR1 were used in the assay. 15 000 GHOST cells were added to each well of a 96-well plate in high glucose Dulbecco's Modified Eagle's medium (DMEM) þ10% fetal bovine serum and incubated for 24 h at 378C and 5% CO 2 . The parental cell line was incubated in medium supplemented with 500 mg/ml of G418, 100 mg/ml hygromycin, and penicillin/streptomycin. The same medium with the addition of 1 mg/ml of puromycin was used for cells with coreceptor transfectants. About 75 ml of pseudovirus incorporating a luciferase reporter gene and full-length env amplicons from population viral RNA as above in addition to a HIV-1 pseudoviral control backbone without envelope and a pNL4-3 positive control psueudovirus were added to wells in a total volume of 150 ml. Plates were incubated for 48-72 h followed by washing, cell lysis, and the quantification of luciferase relative light units using a Fluostar Optima fluorescent plate reader (BMG Labtech, Ortenberg, Germany). All assays were run in triplicate wells and repeated at least twice.
To test whether or not entry into alternative viral coreceptors can be inhibited in vitro, the experiment was repeated using GHOST CXCR6 cells with or without the addition of a rabbit anti-CXCR6 polyclonal antibody (Sigma Aldrich SAB2100513, St. Louis, Missouri, USA) at concentrations ranging from 50 to 1 mg/ml incubated 1 hour prior to addition of pseudovirus and pseudoviral backbone control.
Full-length HIV-1 envelope single-genome analysis
Single-genome amplification and sequencing of fulllength envelope sequences from longitudinal time points were performed based on an existing protocol [43] . Briefly, viral RNA was reversed transcribed followed by nested PCR of various RNA dilutions to achieve 1 or fewer HIV-1 copies per reaction well. Sequences were kept if less than 30% of PCR wells were positive and there were no ambiguous peaks from sequencing chromatograms. Maximum likelihood trees of near full-length envelope sequences were constructed to compare sequence divergence using the PhyML/PAUP plugins for Geneious Pro (Biomatters, San Francisco, California, USA) after statistical selection of best-fit models of nucleotide substitution (jModelTest). Large gaps and sequence segments with ambiguous nucleotide alignments were stripped prior to model selection and phylogenetic analysis.
HIV-1 gag and nef sequencing, and human leukocyte antigen-associated immune escape mutations Full-length population gag and nef gene amplification and sequencing from plasma RNA and PBMC DNA were performed as described [44] . Ambiguous bases were called if minority sequencing chromatogram peaks were 25% or higher of the peak height from bidirectional strands. Known cytotoxic T-lymphocyte epitopes and probable epitopes based on human leukocyte antigen (HLA) specific anchor motifs in the gag and nef protein sequences were identified using the epitope location finder tool from the Los Alamos HIV database.
Assessment of HIV-specific T-cell responses
Interferon-g enzyme-linked immunospot (Elispot) assays were performed on PBMCs using comprehensive HLAspecific peptide panel as described involving 50 000-100 000 cells per reaction well [45] . The number of antigen-specific cells defined by the number of spotforming cells (SFC) per million PMBC was calculated by subtracting the mean negative-control values. An antigen-specific PBMC response was considered positive only if it was at least 55 SFC/10 6 PBMC, at least four times the mean background, and also, at least four times the standard deviation of the number of SFC/10 6 PBMC within the negative controls.
Data analysis
Phylogenic and statistical analysis were performed using Geneious v. R7 (Biomatters) and Prism 5.0 (GraphPad Software, La Jolla, California, USA).
Results

Clinical course and host genetics
We identified two HIV-1 infected men with a CCR5 D32/D32 genotype from a large genome-wide association study of the International HIV Controller Cohort. PCR screening and subsequent full-length CCR5 sequencing confirmed that both CCR5 alleles in these two individuals carried the D32 mutation. Screening revealed that participant A's presumed source partner was CCR5 wild type. Figure 1 shows longitudinal results from clinical viral load monitoring and CD4 þ T-lymphocyte counts for both participants. Participants A and B had sexually acquired HIV-1 infection and experienced asymptomatic viremia of less than 4000 HIV-1 RNA copies/ml with preserved CD4 þ T-cell counts off ART for at least 3.3 and 4.6 years, respectively. Both participants eventually experienced increases in HIV-1 RNA to more than 10 000 copies/ml and decreasing CD4 þ T-cell counts; participant B started ART in January, 2012. Participant A had no known favorable HLA A or B alleles, whereas participant B had one copy of the B Ã 5201 allele, which has been associated with slower HIV-1 disease progression [46] .
Participant A coreceptor usage
Coreceptor usage by HIV-1 obtained from participant A and the presumed source partner was determined by env genotype and by phenotypic assay. The geno2pheno algorithm applied to V3 loop sequences from time points during virologic control off ART (April 2009) and after virologic escape (September 2012) predicted that virus was only able to use CXCR4 for entry [false-positive rates (FPRs) of classifying an R5-virus falsely as X4, of 0.7 and 1.3, respectively]. Phenotypic assays performed at both time points demonstrated the ability to use only CXCR4 for entry ( Fig. 2) . However, the geno2pheno algorithm predicted CCR5 usage from the suspected infecting partner 2 years prior to the first sample obtained from participant A, and CCR5 usage was also observed in phenotypic assays. In addition, a faint, but reproducible signal in CXCR4-expressing cells was observed in assays using viruses pseudotyped with the envelope from virus of participant A's partner, which was completely inhibited by the small-molecule CXCR4 inhibitor AMD3100 (Fig. 2) .
Participant A single-genome analysis
In order to assess viral sequence changes between isolates obtained from participant A's sexual partner and from participant A before and after virologic escape, singlegenome sequencing and phylogenetic analysis of fulllength envelope sequences from plasma RNA were performed. We obtained 49 sequences from plasma collected from participant A's partner in December of 2005, 11 sequences prior to loss of virologic control from participant A (collected in April 2009) and 41 sequences obtained after virologic escape in September 2012. All sequences were determined to be subtype B. Env sequences from participant A and his partner formed separate clusters, but shared a common phylogenetic branch point and were more closely related to each other than to 33 unique subtype B sequences obtained from the Los Alamos HIV-1 sequence compendium (Fig. 2 ). All but one of the viral sequences from participant A's partner were predicted by geno2pheno to use CCR5 alone; phenotypic assay of pseudoviruses incorporating env amplicons from two representative envs sequences confirmed the R5 phenotype of these envelopes (Fig. 3) . The one V3 loop sequence predicted to use CXCR4 and subsequent phenotypic determination of pseudoviruses incorporating this full-length env amplicon revealed pure X4virus. This V3 loop sequence from this virus was more highly related to those of the X4 sequences from participant A, but the non-V3 segment shared greater homology to his other R5 variants (Fig. 3) .
Participant B coreceptor usage
The geno2pheno algorithm of V3 population sequences from participant B 2008 plasma RNA and 2011 and 2012 cell-associated HIV-1 DNA predicted the ability for the virus to use CXCR4 for entry, with FPRs all 1.5% or less as shown in Fig. 4 . However, pseudoviruses derived from 2008 plasma RNA amplicons were only able to use CCR5 for entry in the phenotypic assay, with no significant luciferase signal in cells expressing CXCR4 despite repetition of the experiment with amplicons from two plasma aliquots (Fig. 4) . Pseudoviruses incorporating population cell-associated HIV-1 DNA envelope sequences from 2008 and 2011 were unable to infect U87 cells expressing either CCR5 or CXCR4, but virus incorporating DNA from the 2012 postvirologic escape PBMCs was able to use both CXCR4 and CCR5, although AMD3100 either incompletely suppressed or potentiated entry in CXCR4-expressing U87 cell ( Fig. 4 ).
Amplification and sequencing of HIV-1 env, gag, or pol from plasma RNA after virologic escape was unsuccessful despite repeated attempts with primers spanning various HIV-1 subtypes. Amplification was also unsuccessful following attempts to amplify virus by coculture in vitro.
Alternative coreceptor usage
Given the lack of CXCR4 usage determined by phenotypic assay from participant B's virus, pseudoviruses incorporating plasma RNA population env amplicons from 2008 were tested on GHOST cells expressing CD4 þ alone, or alternative viral coreceptors as shown in Fig. 5 . Low but reproducible levels of entry determined by luciferase activity were observed in cell lines expressing CXCR6, and to a lesser extent GPR15 and CCR1. No entry was observed in cells expressing CXCR4, but a strong signal was observed in cells expressing CCR5. Addition of 0.05-1 mg/ml of anti-CXCR6 antibody to the assay incorporating CXCR6-transfected GHOST cells resulted in a 27-41% reduction in viral entry as Envelope sequences were obtained from plasma RNA prior to virologic escape (2008) and from cell-associated DNA from 2011 and 2012, after rising viral loads. The geno2pheno (G2P) algorithm predicted that all virus or proviruses would use CXCR4 given low FPRs and positively charged amino acids in V3 position 11 (arginine). However, pseudoviruses incorporating population envelope sequences from 2008 RNA used only CCR5 for entry. HIV-1 pseudoviruses incorporating cell-associated DNA envelope sequences from 2012 were able to use CXCR4 and CCR5 (dual/mixed tropic), but at lower levels than viruses derived from RNA. Pseudoviruses derived from DNA in 2008 and 2011 were unable to enter U87 cells expressing either CXCR4 or CCR5. FPR, false-positive rate. from various time points off ART (RNA from April 2009 and September 2012 for participant A; RNA from October 2008, and DNA from February 2011 and June 2012 for participant B). One novel mutation in a known HLA B Ã 4001-restricted nef epitope from participant B PBMC DNA previously associated with immune escape [47] was observed after virologic escape compared with prior RNA or DNA sequences. No amino acid changes or known escape mutations in any other epitopes were observed in samples from all other time points from participants A and B. Viral RNA was unable to be amplified or detected from postescape plasma samples from participant B as above.
HIV-1-specific immune responses following virologic escape Participant A's PBMCs from 2012 demonstrated a strong HIV-1-specific T-cell immune response to the B Ã 1501-GY9(p24) restricted epitope by interferon-g Elispot assay (1730 SFC/10 6 PBMCs), and a weaker response to A Ã 11-SK9 (env; 60 SFC/10 6 PBMCs); no significant responses were detected to other peptides spanning various HIV-1 regions from postviral escape samples. Participant B PBMCs from 2012 demonstrated activation upon stimulation by several HLA-restricted epitopes spanning env, p24, nef, reverse transcriptase, p17, and gp 41 (Supplementary Table 1 , http://links.lww.com/QAD/ A666). A particularly strong response was demonstrated for the B Ã 4001-KL9 (nef) epitope (1000 SFC/10 6 PBMCs) postvirologic escape, the epitope described above with a novel amino acid mutation in proviral DNA following virologic escape.
Discussion
We studied two CCR5 D32/D32 HIV-1-infected participants that experienced virologic control without ART for approximately 3-4 years after diagnosis. Investigation of viral evolution, coreceptor usage, and immune control yielded several important and novel findings, including the presence of HIV-1 that appears to engage alternative corececptors rather than CXCR4 for entry, and the ability for an individual without functional CCR5 to become infected with a minority X4 viral population. A majority of CCR5 D32/D32 individuals experienced rapid disease progression [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , an observation previously attributed to the fact that all described CCR5 D32/ D32 participants were infected with X4-dual/mixed tropic virus. However, participant A experienced virologic control off ART with plasma HIV-1 RNA levels under 4000 copies/ml years after diagnosis with preserved CD4 þ T-cell counts greater than 400 cells/ml with X4 virus and no known favorable HLA alleles. He had a relatively narrow HIV-1-specific postvirologic escape PBMC response to HLA-restricted peptides and no known cytotoxic T-lymphocyte escape mutations in gag or nef genes. Taken together this data suggest that rapid disease progression cannot be attributed to the presence of X4 virus alone.
Participant A appears to have been infected from a pool of HIV-1 viruses that predominately uses CCR5 for entry, and our findings suggest that minority X4 viruses are able to establish infection in hosts without functional CCR5. Although no direct link could be demonstrated between viruses from participant A and his suspected infecting partner, full-length env sequences from both individuals shared a common phylogenic branch point and were distinct from a subtype B compendium envelope sequence outgroup. Furthermore, the V3 loop sequence of participant A's partner X4 viral strain was more highly related to participant A than to his own R5 viral sequences. These env sequences shared a 4 aminoaciddeletion in a V3 loop region previously associated with the ability for an R5 HIV-1 strain to use CXCR4 after weeks of in-vivo replication and appearance of the deletion [48] . Envelope V3 loop sequences from both participant A and B differed from the HIV-1 clade B consensus sequence by 5-10 amino acid positions, but further study of a larger number of patients will be needed in order to understand the relationship between V3-loop diversity and viral entry in cells lacking functional CCR5.
The lack of matching full-length envelope sequences between participant A and his partner may have been due to several factors, including the limited number of sequences able to be obtained by single-genome analysis, and years of viral replication between sample time points.
RNA extraction and single-genome analysis of the participant and partner envelope sequences were performed months apart using different reagents, minimizing the potential for cross-sample PCR or sequencing contamination.
Viremic control in participant B may be related to several unique virologic and immunologic findings. For example, participant B was found to have one copy of a HLA B Ã 52 allele previously associated with slower HIV-1 progression [37, 46] . The participant also developed a novel amino acid mutation in a known HLA-B Ã 4001restricted epitope identified in HIV-1 DNA following rapid increase in viral loads [47] . However, a HIV-1specific PBMC response to this epitope suggests immune adaptation in the setting of ongoing viral replication, and does not necessarily explain years of virologic control off ART.
Participant B also had evidence of plasma-derived HIV-1 that was unable to use CXCR4 for entry in phenotypic experiments despite genotypic prediction to do so. However, pseudoviruses derived from participant B's previrologic escape plasma were able to engage one or more alternative coreceptor for entry (e.g. CXCR6).
HIV-1 normally prefers to use CXCR4 or CCR5 for entry [31] , and the exclusive use of other coreceptors may in part explain the observed low-level viremia and stable CD4 þ T-cell counts off ART for over 4 years. It is also possible that the virus used other, unidentified mechanisms for cell entry or cell-to-cell transmission. Interestingly, the exclusive use of the coreceptor GPR15 has been reported in one CCR5 wild-type individual in the setting of primary infection with a very high peak viral load peak (87.7 million RNA copies/ml), suggesting efficient use of this coreceptor during early stages of infection [35] . HIV-1 able to use a broad range of alternative coreceptors has also been observed in a CCR5 D32/WT individual, but unlike our participant, virus was able to use CXCR4 for entry [36] . Of note, small-molecule CCR5 inhibition has not been shown to lead to selection of virus able to use alternative coreceptors for entry in vivo, in which a majority of drug failures are due to selection of preexisting X4 minority variants [49] .
Pseudoviruses derived from participant B's post viral escape population DNA env sequences were able to use low levels of CXCR4 in addition to CCR5 in the phenotypic assays. It is not known, however, whether or not plasma-derived viruses from postvirologic escape time points had the capacity to use CXCR4 in vivo. It is possible that the virus evolved to use CXCR4 or alternative coreceptors more efficiently over time leading to virologic escape. Unfortunately, repeated attempts to amplify HIV-1 RNA from sample time points after virologic escape were unsuccessful; sample integrity may have contributed to the lack of amplifiable RNA.
In summary, we report the two cases of HIV-1control off ART in the setting of CCR5D32 homozygosity, although viremic control was not durable. Our study demonstrates that individuals may be infected by minority X4 viruses from a population that predominately uses CCR5 for entry, and that viruses may bypass traditional HIV-1 coreceptors (CCR5 and CXCR4) completely by engaging alternative coreceptors to establish and propagate HIV-1 infection in individuals lacking functional CCR5.
